Diagnostic Radiopharmaceuticals and Contrast Media Market Size, Share and Growth Outlook, 2026

Diagnostic Radiopharmaceuticals and Contrast Media Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Diagnostic Radiopharmaceuticals and Contrast Media Market size is forecast to increase from $6.63 Billion in 2026 to $11.48 Billion in 2034 at a CAGR of 7.1% between 2026 and 2034.

The Diagnostic Radiopharmaceuticals and Contrast Media market report provides detailed analysis and outlook of Diagnostic Radiopharmaceuticals and Contrast Media segments including By Product Type: (Radiopharmaceuticals, Contrast Media), By Imaging Modality (SPECT, PET), By Contrast Media Type: (Iodinated, Gadolinium-based, Microbubble, Barium-based), By Application: (Cardiovascular, Oncology, Gastroenterology, Neurology), By End-User: (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers, Cancer Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Diagnostic Radiopharmaceuticals and Contrast Media Industry Overview

The diagnostic radiopharmaceuticals and contrast media industry is experiencing significant growth driven by rising demand for precision diagnostics, molecular imaging, advanced cancer detection, and next-generation imaging agents. Healthcare systems worldwide are increasingly adopting specialized contrast media and radiopharmaceuticals to improve the accuracy of computed tomography (CT), magnetic resonance imaging (MRI), X-ray imaging, and positron emission tomography (PET) examinations. Advances in targeted molecular imaging, localized manufacturing infrastructure, theranostic development, and safer contrast agent formulations are transforming the diagnostic imaging landscape. As healthcare providers seek enhanced diagnostic confidence, improved patient safety, and greater operational efficiency, innovation across diagnostic radiopharmaceuticals and contrast media continues to accelerate.

Expansion of Contrast Media Manufacturing Strengthening Global Supply Chains

A major trend shaping the diagnostic radiopharmaceuticals and contrast media market is the expansion of regional manufacturing capacity to support growing imaging demand. Bracco officially commenced operations at its newly constructed manufacturing facility in India, significantly strengthening local production capabilities for diagnostic contrast agents and iodinated imaging media. The facility has been strategically established to support the scaling requirements of India’s expanding healthcare infrastructure, including large public healthcare initiatives such as the Ayushman Bharat program.
The new manufacturing site enhances Bracco’s localized fill-finish operations and production capacity for premium contrast media used in complex CT scans and X-ray imaging procedures. Localized manufacturing improves supply chain resilience, reduces dependence on imported imaging agents, and supports faster access to critical diagnostic products across the Asia-Pacific region. The increasing investment in contrast media manufacturing facilities, diagnostic imaging supply chains, iodinated contrast agents, and regional production infrastructure is becoming a key driver of growth within the diagnostic radiopharmaceuticals and contrast media industry.

Gadolinium-Free MRI Contrast Agents Advancing Patient Safety

Innovation in MRI contrast media is emerging as another major focus area within the diagnostic radiopharmaceuticals and contrast media market. GE HealthCare announced that the first patient has been dosed in its Phase II/III LUMINA clinical trial evaluating an investigational manganese-based macrocyclic MRI contrast agent. Operating under FDA Fast Track designation, the candidate represents a significant advancement in the development of gadolinium-free contrast media.
The novel imaging agent utilizes manganese, a naturally occurring trace element that can be efficiently processed and cleared by the body, as an alternative to conventional gadolinium-based contrast agents (GBCAs). The objective is to provide equivalent diagnostic performance for body imaging and central nervous system imaging while addressing growing interest in alternative MRI contrast technologies. As healthcare providers increasingly focus on patient safety, innovation in gadolinium-free MRI contrast agents, macrocyclic contrast media, advanced MRI diagnostics, and next-generation imaging agents is becoming a critical area of industry development.

Targeted Radiopharmaceuticals Expanding Precision Molecular Imaging

The diagnostic radiopharmaceuticals market is also benefiting from rapid advancements in targeted molecular imaging technologies. Lantheus Holdings received U.S. FDA approval for PYLARIFY TruVu (piflufolastat F18), an optimized formulation of its prostate-specific membrane antigen (PSMA)-targeted PET imaging radiopharmaceutical. The updated platform is designed to improve manufacturing efficiency and enhance supply chain flexibility while maintaining the clinical value of PSMA-targeted prostate cancer imaging.
The company plans a phased geographic rollout to transition imaging centers to the enhanced formulation, reflecting growing demand for precision oncology diagnostics. The increasing adoption of PSMA PET imaging, molecular diagnostic radiopharmaceuticals, prostate cancer imaging agents, and targeted PET diagnostics continues to strengthen the role of radiopharmaceuticals in personalized cancer care.
Further innovation is occurring within the emerging theranostics segment. Bayer initiated a Phase I clinical trial evaluating BAY 3547926 (225Ac-GPC3), an investigational targeted alpha radiopharmaceutical designed to bind Glypican-3 (GPC3)-expressing tumors in advanced hepatocellular carcinoma. The therapy combines a high-affinity antibody with Actinium-225, enabling highly targeted delivery to cancer cells. Preclinical studies demonstrated rapid clearance from healthy organs alongside concentrated tumor uptake, highlighting the growing convergence of diagnostic imaging and targeted radionuclide therapy.
The development of alpha-emitting radiopharmaceuticals, targeted oncology imaging agents, precision molecular diagnostics, theranostic platforms, and advanced nuclear medicine technologies reflects the industry's transition toward highly personalized diagnostic and treatment pathways. As contrast media innovation, molecular imaging advancements, targeted PET radiopharmaceuticals, and theranostic technologies continue to evolve, the diagnostic radiopharmaceuticals and contrast media industry is becoming an increasingly important pillar of modern precision medicine and advanced diagnostic imaging.

Diagnostic Radiopharmaceuticals and Contrast Media Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Diagnostic Radiopharmaceuticals and Contrast Media market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Bayer AG, GE HealthCare Technologies Inc., Bracco Imaging S.p.A., Guerbet Group, Lantheus Holdings, Inc., Curium, Siemens Healthineers AG, Cardinal Health, Inc., Nordion Inc., NTP Radioisotopes SOC Ltd.. The Diagnostic Radiopharmaceuticals and Contrast Media market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Diagnostic Radiopharmaceuticals and Contrast Media industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Diagnostic Radiopharmaceuticals and Contrast Media Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Diagnostic Radiopharmaceuticals and Contrast Media companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Diagnostic Radiopharmaceuticals and Contrast Media markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Diagnostic Radiopharmaceuticals and Contrast Media Market Competitive Benchmarking and Company Analysis

Leading companies in Diagnostic Radiopharmaceuticals and Contrast Media industry include- Bayer AG, GE HealthCare Technologies Inc., Bracco Imaging S.p.A., Guerbet Group, Lantheus Holdings, Inc., Curium, Siemens Healthineers AG, Cardinal Health, Inc., Nordion Inc., NTP Radioisotopes SOC Ltd.. The Diagnostic Radiopharmaceuticals and Contrast Media market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Diagnostic Radiopharmaceuticals and Contrast Media Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Diagnostic Radiopharmaceuticals and Contrast Media market remains one of the strongest-performing segments in the country.
The US Diagnostic Radiopharmaceuticals and Contrast Media Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Diagnostic Radiopharmaceuticals and Contrast Media market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Diagnostic Radiopharmaceuticals and Contrast Media industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Diagnostic Radiopharmaceuticals and Contrast Media markets

Canada's strong Diagnostic Radiopharmaceuticals and Contrast Media sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Diagnostic Radiopharmaceuticals and Contrast Media market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Diagnostic Radiopharmaceuticals and Contrast Media Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Diagnostic Radiopharmaceuticals and Contrast Media market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Diagnostic Radiopharmaceuticals and Contrast Media population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Diagnostic Radiopharmaceuticals and Contrast Media industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Diagnostic Radiopharmaceuticals and Contrast Media market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Diagnostic Radiopharmaceuticals and Contrast Media sales through 2034

France Diagnostic Radiopharmaceuticals and Contrast Media companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Diagnostic Radiopharmaceuticals and Contrast Media Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Diagnostic Radiopharmaceuticals and Contrast Media distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Diagnostic Radiopharmaceuticals and Contrast Media Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Diagnostic Radiopharmaceuticals and Contrast Media market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Diagnostic Radiopharmaceuticals and Contrast Media industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Diagnostic Radiopharmaceuticals and Contrast Media industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Diagnostic Radiopharmaceuticals and Contrast Media Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Diagnostic Radiopharmaceuticals and Contrast Media market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Diagnostic Radiopharmaceuticals and Contrast Media market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Diagnostic Radiopharmaceuticals and Contrast Media Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Diagnostic Radiopharmaceuticals and Contrast Media Market Segmentation

By Product Type:
Radiopharmaceuticals
Contrast Media
By Imaging Modality
SPECT
PET
By Contrast Media Type:
Iodinated
Gadolinium-based
Microbubble
Barium-based
By Application:
Cardiovascular
Oncology
Gastroenterology
Neurology
By End-User:
Hospitals
Diagnostic Imaging Centers
Ambulatory Surgical Centers
Cancer Research Institutes

Top Companies in Diagnostic Radiopharmaceuticals and Contrast Media Industry

Bayer AG
GE HealthCare Technologies Inc.
Bracco Imaging S.p.A.
Guerbet Group
Lantheus Holdings, Inc.
Curium
Siemens Healthineers AG
Cardinal Health, Inc.
Nordion Inc.
NTP Radioisotopes SOC Ltd.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025